Jiwook Lee, Sung Hyun Park and Young Zoon Kim
Division of Neuro-oncology and Department of Neurosurgery, Samsung Changwon Hospital, Sungkyunkwan
University School of Medicine, South Korea
Purpose: The aims of this study were to investigate the role of the Neurological Assessment of
Neuro-Oncology (NANO) scale in predicting the prognosis of patients with glioblastoma, and
compare these results to predicted data of the Karnofsky Performance Scale (KPS), and Eastern
Cooperative Oncology Group (ECOG)/World Health Organization (WHO) performance status.
Materials: The medical records of 76 patients with a new diagnosis of histologically ascertained
glioblastoma for recent 13 years at the authors’ institution were retrospectively reviewed. Clinical
factors, including epidemiologic, radiologic, and therapeutic values were reviewed as well as the
performance status assessed by the KPS, ECOG/WHO performance status, and NANO scale.
Results: At initial diagnosis, the mean value (± SD) of KPS score, ECOG/WHO performance status,
and NANO scale were 81 (± 7.4), 1.3 (± 0.6), and 7.3 (± 3.8), respectively. Multivariate analysis for
predicting survival showed odds ratios of KPS score, ECOG/WHO performance status, and NANO
scale were 2.502 (≥ 80 vs. <80; p =0.024), 1.699 (0-1 vs. 2-5; p =0.046), and 2.763 (0-7 vs. 8-23; p
=0.020), respectively. At the time of progression, the mean value (± SD) of KPS score, ECOG/WHO
performance status, and NANO scale were 67 (± 6.8), 1.7 (± 0.6), and 15.6 (± 5.2), respectively;
multivariate analysis for predicting survival showed that the odd ratios for KPS score, ECOG/WHO
performance status, and NANO scale were 2.007 (≥ 80 vs. <80; p =0.035), 1.321 (0-1 vs. 2-5; p
=0.143), and 3.182 (0-7 vs. 8-23; p =0.002), respectively.
Conclusion: The NANO scale provided a more detailed and objective measure of neurologic
function than that currently used for predicting the prognosis of glioblastoma patients, especially at
the time of progression.
Glioblastoma; KPS; NANO scale; Prognosis; Prediction; Survival
Lee J, Park SH, Kim YZ. Role of Neurological Assessment of the Neuro-Oncology (NANO) Scale in the
Treatment of Glioblastoma Patients Ann Neurol Surg. 2018; 2(1): 1009.